2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 271-273
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Biological Therapies, Transplantation, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Telemedicine, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, AML, APL, Clinical Research, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Study Population, Human
PAPER

583 Remote continuous monitoring enables homebound autologous hematopoietic cell transplantation without a full-time caregiver and reduces costs in patients with multiple myeloma

Heather J. Landau, MD, Danielle Lutrario, RN, BS2, Meredith Caprio3, Courtney McElrath4, Nicole LeStrange5, Elizabeth Rodriguez6, Sarah Samorodnitsky, PhD7, Jin Zheng8, Eugene Brailovski, MD9, Parastoo B. Dahi, MD10, Patrick Gould, MD11, Eric Matthew Jurgens, MD12, Jonathan Peled, MD/PhD13, Michael Scordo, MD14, Gunjan L. Shah, MD, MS15, Saad Z. Usmani, MD16, Miguel-Angel Perales, MD17, Sergio Giralt, MD18
1 Memorial Sloan Kettering Cancer Center, New York City, United States
2 Memorial Sloan Kettering Cancer Center, New York City, United States
3 Memorial Sloan Kettering Cancer Center, New York City, United States
4 Memorial Sloan Kettering Cancer Center, New York City, United States
5 Memorial Sloan Kettering Cancer Center, New York City, United States
6 Memorial Sloan Kettering Cancer Center, New York City, United States
7 Memorial Sloan Kettering Cancer Center, New York City, United States
8 Memorial Sloan Kettering Cancer Center, New York City, United States
9 McGill University, Montreal, Quebec, Canada
10 Memorial Sloan Kettering Cancer Center, New York City, United States
11 Memorial Sloan Kettering Cancer Center, New York City, United States
12 Memorial Sloan Kettering Cancer Center, New York City, United States
13 Memorial Sloan Kettering Cancer Center, New York City, United States
14 Memorial Sloan Kettering Cancer Center, New York City, United States
15 Memorial Sloan Kettering Cancer Center, New York City, United States
16 Memorial Sloan Kettering Cancer Center, New York City, United States
17 Memorial Sloan Kettering Cancer Center, New York City, United States
18 Memorial Sloan Kettering Cancer Center, New York City, United States

Introduction: Autologous hematopoietic cell transplantation (AHCT) is standard consolidation for eligible patients (pts) with multiple myeloma (MM). The significant investment of time and caregiver (CG) requirements represent a barrier to access.  AHCT occurs in inpatient or outpatient settings and mandates a 24hr CG upon release from the hospital or for the duration of AHCT, respectively.  Providing post-tranplant care in a homebound setting where nurses deliver care to pts at home was studied to reduce CG burden and was found to be safe and feasible (Landau et al., 2022).  Pt and CG satisfaction with the program was high despite an ongoing requirement for a full-time CG.  We designed a trial to test the hypothesis that continuous remote monitoring can replace the need for a full-time CG.  Here, we report the results of Homebound ASCT pts who underwent continuous heart rate (HR) monitoring while receiving care at home without the need for a full-time CG. 

Methods: This prospective, investigator-initiated pilot trial included homecare beginning day+ 1 after ASCT. Pts had a telemedicine visit with an advanced practice provider (APP) each morning after vital signs (HR, blood pressure, oxygen saturation, temperature, weight) were transmitted through a dashboard.  Continuous HR monitoring from 8am-6pm using Fitbit with prespecified alarms served as a surrogate for the CG.  Registered nurses visited the pts homes on day+3 and day+5 through engraftment to collect labs and provide interventions as needed.  Only blood products required pts to come to clinic.  This pilot trial included a 10 pt safety run-in with continuous HR monitoring from 8am-6pm, but also a 24hr CG.  Once the technology proved reliable, 14 more pts were enrolled without mandating a full-time CG.  The primary endpoint was the admission rate at 21 days following AHCT. Secondary objectives included safety, pt quality of life (QOL) (MD Anderson Symptom Inventory, Functional Assessment of Cancer Therapy- Bone Marrow Transplantation) and pt and CG satisfaction measures (Pt Distress Thermometer, CG Reaction Assessment, respectively). Time sheets tracked CG activities.  Cost analysis compared Homebound AHCT pts (N=24) to contemporaneous MM pts receiving outpatient (OP) AHCT (N=142) or inpatient (IP) AHCT (N=82) because a CG was not available.  Costs were estimated using hospital billing and financial data, which allocate expenses based on services that generate charges such as clinic visits, labs, medications, and inpatient stays.

Results: Following the safety run-in which demonstrated that continuous monitoring data was reliably transmitted in all 10 pts, 14 (median age 61; 57% female) with MM received care at home starting day +1 following AHCT. Pts remained in the program for an average of 12 days and required a median of 3 (range 0-6) OP visits, exclusively for transfusions, while receiving home care. Pts received a median of 4 (range 2-8) platelet and 0 (range 0 -2) RBC transfusions. Within the first 21 days post-AHCT, 3/14 (21%) pts required hospitalization for a median of 7 days (range, 2 - 13). Only 1 pt had a documented infection (Gemella haemolysans) in the setting of mucositis. Two pts admitted for febrile neutropenia (N=1) and diarrhea/hypotension (N=1) had concurrent Engraftment Syndrome.  No pt required ICU admission and there were no deaths.  Among 14 CGs, the median age was 55 and 57% were female. 10/14 CGs were spouses, 3 children, and 1 sister.  CG timesheets indicated 3 CGs worked for 2-8 hours each day, 6 took breaks for “recreation” and 9 went shopping or tended to other household tasks. Pt QOL and Pt and CG satisfaction surveys were uniformly favorable (data not shown).  The estimated mean total cost of care for Homebound pts was $93,831 per pt and averaged 2.3 IP hospital days; whereas the mean OP or IP AHCT cost was $111,971 or $130,657 per pt, and averaged 4.4 or 18.1 IP hospital days, respectively.  Compared to OP AHCT, Homebound AHCT saved $18,140 per pt and 2.1 IP days.  Compared to IP AHCT for pts without a CG, Homebound AHCT saved $36,826 per pt and 15.8 IP days. 

Conclusions: Remote continuous monitoring enables pts to undergo Homebound AHCT safely without the need for a full-time CG and results in encouraging pt and CG satisfaction.   Meaningful cost and IP bed savings supports resourcing and expanding the Homebound cellular therapy program to minimize the need for MM pts to be hospitalized for AHCT and other cellular therapies. 

Heather J. Landau, MD: Nexcella - Honoraria; Alexion - Honoraria; Karyopharm - Honoraria; Arcellx - Honoraria; Bristol Myers Squibb - Honoraria; AbbVie - Honoraria; Pfizer - Honoraria; Protego - Research Funding; Alexion - Research Funding; AbbVie - Research Funding; Nexcella - Research Funding; Prothena - Research Funding; AbbVie - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Nexcella - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony)